Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients with hemophilia A or B without inhibitors. HYMPAVZI currently hold ...

以上内容基于公开资料整理，不构成投资建议。 近期事件 2026年2月11日，上海证券报报道跨国药企2025年业绩，辉瑞以625.79亿美元营收位列行业前六，但受 新冠产品需求下滑影响（如复必泰营收降33%），成为前十药企中两家营收下降企业之一。非新冠产品 如抗凝药Eliquis（营收80亿美元，增8%）和肺炎疫苗Prevnar（营收65亿美元）贡献稳定增长，抵消部 分下滑。 股票近期走势 近7天（2026年2月5日至11日），辉瑞股价区间涨跌幅为3.55%，振幅5.53%，最高价达27.94美元（2月 11日），最低价26.46美元（2月5日）。截至2月11日收盘，股价报27.73美元，单日涨0.43%，成交额 11.57亿美元。年初至今累计涨幅13.23%，表现优于制药板块（同期跌0.02%）。 经济观察网 根据辉瑞于2026年2月4日发布的2025年全年财务报告，公司总营收为626亿美元，同比下降 2%，但剔除新冠产品（如Comirnaty和Paxlovid）影响后，核心业务营收同比增长6%，反映出非新冠业 务的稳健增长。调整后每股收益（EPS）为3.22美元，同比增长4%，主要受益于成本削减计划和运营效 ...

Key Takeaways Pfizer's COVID sales fell sharply, while non-COVID revenues rose 6% operationally in 2025.PFE's new and acquired drugs generated $10.2B in 2025, up about 14% year over year.Pfizer faces a 2026-2030 LOE cliff as Eliquis and other key drugs near patent expiry.Sales of Pfizer’s (PFE) COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their sales came down to around $11 billion in 2024 and $6.7 billion in 2025 from $56.7 billion in 2022. In addition to l ...

Key Takeaways PFE beat Q4 earnings & sales estimates, but revenues fell 3% operationally due to sharp COVID product declinePFE reported positive phase IIb obesity data for PF'3944, strengthening its pipeline after the Metsera buyout.Pfizer's 2026 outlook indicates lower revenues and EPS, pressured by COVID erosion, LOEs and higher costs.Pfizer’s (PFE)  fourth-quarter results were strong as it beat estimates for both earnings and sales. Total revenues declined 3% on an operational basis due to a 40% decline ...

2026 年 2 月 5 日 招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 公司点评 全球市场观察 公司点评 辉瑞（PFE US，买入，目标价：35.46 美元） - 减重管线数据推动估值重估 潜力 中国股指收涨，港股能源、地产与原材料领涨，信息科技、可选消费与医疗 跑输。南下资金净买入133.73亿港元，腾讯、阿里巴巴与小米净买入居前， 中芯国际、华虹半导体与钧达股份净卖出最多。A 股煤炭、建材与地产领涨， 传媒、通信与计算机跑输。马斯克团队考察光伏产业链，上市公司密集回应。 中国光伏行业协会表示太空光伏技术仍处于探索和验证的初期阶段。 美股指数下跌，信息技术、通讯服务与可选消费领跌，能源、材料与地产领 涨。美股市场软件股抛售潮继续蔓延至半导体、AI 概念股等领域，宏观数据 喜忧参半未能给市场提供支撑。资金从科技股、成长股与高估值板块向能源、 材料股、价值股与低估值板块切换。AMD 疲弱指引后暴跌 17%，拖累半导 体板块下挫，Palantir、Snowflake、Datadog 等软件与 AI 相关个股继续承压。 谷歌All in AI，第4季度云收入猛增48%，今年支出指引接近翻倍大超预期 ...

2026年2月5日 CMB国际 | 全球市场 | 股权研究 | 公司更新 辉瑞公司（PFE美国） 肥胖领域风险降低推动重估潜力 辉瑞公布了强劲的2025年第四季度业绩，收入为176亿美元（基本符合我们180亿美元 的预估），调整后净收入为38亿美元（超出我们33亿美元的预估）。尽管2025财年收入 达到626亿美元（同比下降2%），但排除COVID-19产品（Comirnaty和Paxlovid）的经 营收入同比增长6%，凸显了公司业务的强劲基础。2025财年调整后摊薄每股收益同比 增长4%至3.22美元，反映了成本削减举措的成功实施。管理层重申了2026年收入预期 为595亿美元至625亿美元，调整后每股收益为2.80美元至3.00美元。我们预计2026财年 预期将充满催化剂，包括长效GLP-1和长效胰淀素项目的关键数据公布，肥胖产品组合 和PF'4404（PD-1/VEGF）的积极临床进展，以及2L+非小细胞肺癌中SV的III期数据和 Elrexfio在复发/难治性多发性骨髓瘤中的数据。我们认为这些里程碑有望推动显著的价 值重估。 VESPER-3读数验证了每月剂量区分。 辉瑞公布了其长效GLP-1（PF ...

Market Performance - The Hang Seng Index closed at 26,847, with a slight increase of 0.05% for the day and a year-to-date increase of 4.75% [1] - The Hang Seng Technology Index decreased by 1.84% for the day and is down 2.71% year-to-date [1] - The US stock market saw the Dow Jones increase by 0.53%, while the S&P 500 and Nasdaq fell by 0.51% and 1.51%, respectively [1] Sector Performance - In the Hong Kong market, the financial sector increased by 0.66% and is up 8.51% year-to-date, while the industrial sector decreased by 0.48% [2] - The real estate sector in Hong Kong saw a significant increase of 1.99% for the day and is up 17.13% year-to-date [2] Capital Flows - Southbound funds recorded a net inflow of 13.373 billion HKD, with Tencent, Alibaba, and Xiaomi being the top net buyers [3] - In contrast, SMIC, Hua Hong Semiconductor, and Jun Da Co. were the most sold stocks [3] US Market Trends - The US stock market experienced a sell-off in technology stocks, particularly in software and semiconductor sectors, with AMD's weak guidance leading to a 17% drop [3] - The S&P 500 software sector has seen an average decline of 25% since reaching a historical high last October [3] Company Analysis: Pfizer (PFE US) - Pfizer reported strong Q4 2025 earnings with revenue of 17.6 billion USD, slightly below the expected 18.1 billion USD, but adjusted net income exceeded expectations at 3.8 billion USD [4] - The company anticipates 2026 revenue between 59.5 billion to 62.5 billion USD, with adjusted EPS guidance of 2.80 to 3.00 USD [4] - Key upcoming milestones include data readouts for long-acting GLP-1 and Amylin projects, which are expected to drive significant valuation re-evaluation [4] Clinical Developments - Pfizer's VESPER-3 study showed a 12.3% weight loss effect at the 28-week mark for its long-acting GLP-1 candidate, with a potential 15.8% weight loss projected for a higher dose [5] - The company plans to initiate a Phase 3 study for the higher dose later this year, with detailed data expected at the ADA conference in June [5] Oncology Pipeline - Pfizer is advancing its PD-1/VEGF and ADC combination therapies, with ongoing Phase 3 trials for PF'4404 in colorectal cancer and additional trials planned for 2026 [6] - The market narrative is shifting towards pipeline execution strength, with obesity products and PF'4404 clinical progress expected to drive stock price increases [6]

Core Insights - Pfizer demonstrated robust operational resilience during its strategic transformation phase, with total revenue reaching $62.6 billion in 2025, reflecting a 6% growth in core business excluding COVID-related products [1][4] - The company maintained its 2026 performance guidance while revealing an active product pipeline, expecting to initiate approximately 20 key clinical trials in 2026, laying the foundation for long-term growth [1][4] Financial Performance - Total revenue for Q4 2025 was $17.6 billion, a 1% decrease from Q4 2024, while full-year revenue decreased by 2% to $62.6 billion [2] - Adjusted diluted EPS for Q4 was $0.66, a 5% increase year-over-year, and for the full year, it reached $3.22, up 4% [2][3] - The adjusted sales cost ratio improved to 24.2%, down from 25.8% in 2024, indicating enhanced cost management [8] Business Segments - Non-COVID product lines showed strong structural growth, with cardiovascular and vaccine segments leading the way; Eliquis generated $8 billion in revenue, a growth of 8% [4][5] - The oncology business achieved $16.8 billion in revenue, an 8% increase, with key products like Ibrance and Xtandi maintaining strong market positions despite competition [6] - COVID-related product revenues significantly declined, with Comirnaty and Paxlovid generating $4.4 billion and $2.4 billion respectively, down 18% and 59% year-over-year [7] Strategic Initiatives - Pfizer completed the acquisition of Metsera for approximately $7 billion, marking its entry into the obesity and metabolic disease treatment market [9] - The company is advancing its obesity pipeline, with promising results from the clinical trials of its long-acting GLP-1 receptor agonist [10] - Multiple oncology products received regulatory breakthroughs, enhancing the competitive edge of Pfizer's oncology portfolio [11][12] 2026 Outlook - Pfizer projects 2026 revenue between $59.5 billion and $62.5 billion, including approximately $5 billion from COVID-related products [13] - The company plans to maintain a focus on reducing debt levels and balancing its capital structure, with no share buybacks planned for 2026 [13]

Core Insights - Pfizer reported fourth-quarter 2025 adjusted earnings per share of 66 cents, exceeding the Zacks Consensus Estimate of 57 cents, with a year-over-year earnings increase of 5% [1] - Total revenues for the quarter were $17.6 billion, a decline of 1% year-over-year on a reported basis and 3% on an operational basis, primarily due to decreased revenues from COVID-19 products [2] Revenue Breakdown - International revenues decreased by 4% on an operational basis to $8.44 billion, while U.S. revenues fell by 1% to $9.1 billion [2] - The Primary Care segment saw a 13% operational decline in sales to $7.94 billion, while Specialty Care recorded a 6% increase to $4.77 billion, and Oncology sales rose by 8% to $4.44 billion [3] Product Performance - Eliquis sales in Primary Care rose by 8% to $2.02 billion, although alliance revenues fell short of the Zacks Consensus Estimate of $2.14 billion [4] - Global revenues from the Prevnar family increased by 8% to $1.71 billion, surpassing the Zacks Consensus Estimate of $1.65 billion [5] - Comirnaty sales were $2.27 billion, down 35% year-over-year, but still beat the Zacks Consensus Estimate of $2.0 billion [6] - Paxlovid revenues dropped by 70% year-over-year to $218 million, missing the Zacks Consensus Estimate of $289 million [7] Full-Year Results - For the full year 2025, Pfizer's sales declined by 2% to $62.6 billion, exceeding the Zacks Consensus Estimate of $61.94 billion [14] - Adjusted earnings for 2025 were $3.22 per share, a 4% increase year-over-year, beating the Zacks Consensus Estimate of $3.13 [14] 2026 Guidance - Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, reflecting a decline from 2025 due to lower COVID product revenues and an impending patent cliff [16] - COVID sales are projected to be around $5 billion in 2026, down from approximately $6.7 billion in 2025 [17] - Adjusted earnings per share for 2026 are expected to be in the range of $2.80-$3.00, a decrease from 2025's EPS of $3.22 [17] Research and Development - Pfizer plans to initiate 20 pivotal studies in 2026, including 10 for ultra-long-acting obesity candidates from the Metsera acquisition [26] - Positive top-line data from a phase IIb study on PF-08653944 showed significant weight reduction, positioning Pfizer competitively against other weight loss therapies [20][21]

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning. Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8 billion in Q4 sales. Pfizer actually earned $0.66 (adjusted for one-time items) on sales of $17.6 billion. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » Image source: Getty Images. Pfizer ...